Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2023
119
Period ended Dec 31, 2023
Change on a year earlier
+25.3%
95 in FY2022
History
7 years
Since FY2017
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 119 | +25.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 95 | -5.0% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 100 | -2.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 103 | -20.8% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 130 | +2.4% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 127 | +35.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 94 | – | Form 10-K (filed 2020-02-26) ↗ |
Cite this data
StockData. (2026). Merck Vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M) ($M), annual FY2017–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_vaqta_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.